EGP-437 demonstrated better clinical performance than vehicle control, but did not meet its co-primary endpoints.

Kala Pharmaceuticals Inc. today announced positive top-line results from its confirmatory Phase 3 trial of KPI-121 1% for the treatment of inflammation and pain in patients who have undergone cataract surgery.

A thirty-something year old blind woman has her sight restored and sees her young baby for the first time; a 6-year-old boy regains his sight, and for the first time in his life, he sees the face of his parents.

Johnson & Johnson announced it will acquire Abbott Medical Optics for more than $4 billion. The deal is expected to close in the first quarter of 2017.

ATLANTA – Alcon (ACL), a division of Novartis (NVS), is investing $250 million into an expansion of its Atlanta-area facility that will add more than 300 jobs, the Atlanta Business Chronicle reported this morning. The expansion will allow Alcon to focus on the manufacturing and development of contact lenses, including Dailies, AquaComfort Plus, Dailies Total1 […]